Participants receiving the antibody treatment were also able to take less additional migraine medication compared with those in the placebo group.
Research presented at the Congress of the European Academy of Neurology 2017 confirms that cannabinoids are as suitable for preventing migraine attacks as other pharmaceutical treatments.
This review explores the limitations of the present technology and current challenges of SCS before reviewing some of the most important recent advances.
A large-scale, population-based study has demonstrated a relationship between persistent pain and cognitive decline.
The new retrospective population-based cohort study from the Mayo Clinic included data from 1993 patients with polyneuropathy.
Dr Deer discusses his career highlights, most memorable patient cases, and looks ahead at future challenges and trends in the field of neuromodulation.
This article focuses the choice of surgical treatment in an unoperated patient with clinically established trigeminal neuralgia.
Eric Wasserman discusses tells us more about his work, uses for noninvasive brain stimulation, and the potential for neuromodulation in the treatment of neurological disorders.
This Editorial article provides an insight into how pharmacogenomics can assist in guided dosing of fentanyl for the treatment of pain.